Zai Lab Reports 15% Revenue Growth in 2025, Advances Key Oncology and Immunology Programs
Event summary
- Zai Lab reported $460.2 million in total revenue for 2025, up 15% year-over-year.
- Product revenue grew 17% YoY in Q4 2025, driven by XACDURO and NUZYRA.
- Key pipeline advancements include zoci (DLL3-targeting ADC) and ZL-1503 (IL-13/IL-31Rα bispecific antibody).
- KarXT received NMPA approval for schizophrenia in China, with commercial launch planned for Q2 2026.
- Net loss narrowed to $175.5 million in 2025 from $257.1 million in 2024.
The big picture
Zai Lab's 2025 results reflect steady commercial progress alongside aggressive pipeline investments, positioning it as a key player in China's biopharma sector. The company's focus on global innovation pipelines and regional launches underscores its strategy to balance near-term revenue growth with long-term value creation. Success will hinge on executing against critical clinical and regulatory milestones in 2026.
What we're watching
- Pipeline Execution
- The pace at which Zai Lab advances zoci and ZL-1503 into pivotal studies will determine its long-term growth trajectory.
- Commercial Momentum
- Whether KarXT can achieve significant market penetration in China following its approval and launch.
- Regulatory Milestones
- The timing of potential NMPA approvals for Tisotumab Vedotin and TTFields in pancreatic cancer will impact revenue diversification.
Related topics